Breast Cancer is Only Pharmaceutical Pipeline with over 1000 Drugs in Development

The breast cancer treatment pipeline, with 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to GBI Research.

The company’s latest report states that factors driving such innovation and potential for breakthrough drugs include a very large and growing patient pool, a well-established market with multiple unmet needs, and a robust understanding of the disease pathophysiology, facilitating the development of novel compounds that may fill such needs.

While the cure rate for early-stage breast cancer is currently high, and the safety and tolerability profiles of existing monoclonal Antibodies (mAbs) are strong, more advanced forms of the disease, such as metastatic cancer, are not so treatable.

GBI analyst Dominic Trewartha commented: “Due to the highly complex and polygenic nature of breast cancer, it is unlikely that the inhibition of a single target will be sufficient to substantially improve the prognosis in the clinic.

“However, it is far more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, will be able to do this, which will positively change the clinical landscape.”

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes